Beam Therapeutics (BEAM) · BEAM-301
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: 2025
data anticipated in 2025
EX-99.1 · filed · SEC filing
After
Stated timing: 2026
BEAM-301 in a Phase 1/2 clinical trial, and expect to report initial clinical data in 2026
· filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/BEAM-beam-301-2026-02-24, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/BEAM-beam-301-2026-02-24
Beam Therapeutics (BEAM) pipeline and stated timing · Calendar · Companies A–Z
A Form 10-K is a company’s annual report to the SEC, with audited financial statements.